News >

Daratumumab Plus Carfilzomib and Dexamethasone Improves PFS in Myeloma

Jason M. Broderick @jasoncology
Published: Monday, Sep 16, 2019

Ajai Chari, MD, an associate professor in hematology and medical oncology at Mount Sinai Hospital

Ajai Chari, MD

Adding daratumumab (Darzalex) to carfilzomib (Kyprolis) and dexamethasone (DKd) improved progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma, according to topline findings from the phase III CANDOR study.1

The investigators considered the regimen to be well tolerated. Grade 3/4 TEAEs occurring most frequently included thrombocytopenia (31%), lymphopenia (24%), anemia (21%), and neutropenia (21%).

References

  1. Genmab announces positive topline results in phase III study of daratumumab in combination with carfilzomib and dexamethasone in relapsed or refractory multiple myeloma. Genmab. Published September 13, 2019. Accessed September 16, 2019. https://bit.ly/2kNde7M.
  2. Amgen announces phase 3 CANDOR study combining Kyprolis® (carfilzomib) and Darzalex® (daratumumab) meets primary endpoint of progression-free survival. Amgen. Published September 13, 2019. Accessed September 16, 2019. https://bit.ly/2mgsnPn.
  3. Chari A, Martinez-Lopez J, Mateos MV, et al. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2019;134(5):421-431. doi: 10.1182/blood.2019000722.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x